Linezolid-related adverse events predictive score (LAPS): Usefulness in clinical practice

Int J Antimicrob Agents. 2015 Dec;46(6):727-8. doi: 10.1016/j.ijantimicag.2015.09.002. Epub 2015 Sep 30.

Authors

R Buzelé¹, A Lemaignen¹, X Pourrat², P Rosset³, G Gras¹, J Druon³, M C Bernard¹, B Sautenet⁴, F Bastides¹, L Bernard⁵

Affiliations

¹ Department of Infectious Diseases, University Hospital Tours, France.
² Department of Pharmacy, University Hospital Tours, France.
³ Department of Orthopaedics, University Hospital Tours, France.
⁴ Department of Nephrology and Clinical Immunology, University Hospital Tours, France.
⁵ Department of Infectious Diseases, University Hospital Tours, France. Electronic address: louis.bernard@univ-tours.fr.

PMID: 26526894
DOI: 10.1016/j.ijantimicag.2015.09.002

No abstract available

Publication types

Letter

MeSH terms

Anti-Bacterial Agents / adverse effects*
Anti-Bacterial Agents / therapeutic use
Humans
Linezolid / adverse effects*
Linezolid / therapeutic use
Middle Aged
Retrospective Studies

Substances

Anti-Bacterial Agents
Linezolid